Prelude Therapeutics Incorporated Common Stock (PRLD) Stock
Key stats
- Market cap
- $301.66M
- Price / Earnings ratio
- -5.0x
- EPS (TTM)
- -$0.73
- Volume
- Loading
- 52-week high
- $6.83
- 52-week low
- $1.21
Source: third-party data provider, as of November 13, 2026
Compare with PRLD
Recent news

Prelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte Option
Prelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte Option
PRLD

Down 27.4% in 4 Weeks, Here's Why Prelude Therapeutics (PRLD) Looks Ripe for a Turnaround
Down 27.4% in 4 Weeks, Here's Why Prelude Therapeutics (PRLD) Looks Ripe for a Turnaround
PRLD

Prelude Therapeutics Teams Up With Lilly To Test Experimental Breast Cancer Drug In Phase 1 Trial
Prelude Therapeutics Teams Up With Lilly To Test Experimental Breast Cancer Drug In Phase 1 Trial
PRLD

Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High?
Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High?
PRLD
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 48.14
- MACD 12/26/9
- -0.07
- EMA 9 of MACD
- -0.10
- MACD histogram
- 0.03
- SMA 50
- $4.07
- Price below SMA 50
- EMA 50
- $4.05
- Price below EMA 50
- SMA 200
- $4.08
- Price below SMA 200
- EMA 200
- $3.74
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Prelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte Option
Prelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte Option
PRLD

Down 27.4% in 4 Weeks, Here's Why Prelude Therapeutics (PRLD) Looks Ripe for a Turnaround
Down 27.4% in 4 Weeks, Here's Why Prelude Therapeutics (PRLD) Looks Ripe for a Turnaround
PRLD

Prelude Therapeutics Teams Up With Lilly To Test Experimental Breast Cancer Drug In Phase 1 Trial
Prelude Therapeutics Teams Up With Lilly To Test Experimental Breast Cancer Drug In Phase 1 Trial
PRLD

Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High?
Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High?
PRLD

Prelude Therapeutics (PRLD) Upgraded to Buy: Here's Why
Prelude Therapeutics (PRLD) Upgraded to Buy: Here's Why
PRLD

Wall Street Analysts Think Prelude Therapeutics (PRLD) Could Surge 33.59%: Read This Before Placing a Bet
Wall Street Analysts Think Prelude Therapeutics (PRLD) Could Surge 33.59%: Read This Before Placing a Bet
PRLD

Why Did PRLD Stock Surge 13% Today?
Why Did PRLD Stock Surge 13% Today?
PRLD

New Strong Buy Stocks for January 25th
New Strong Buy Stocks for January 25th
PRLD

The 7 Worst Stocks to Buy Now
The 7 Worst Stocks to Buy Now
PRLD
News tone: automated (AI) classification of the article's content, not a price prediction.
About Prelude Therapeutics Incorporated Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Krishna Vaddi D.V.M., Ph.D. | Founder, CEO & Director | 1966 |
| Mr. Bryant David Lim J.D. | CFO, Chief Legal Officer & Corporate Secretary | 1971 |
| Dr. Peggy A. Scherle Ph.D. | Chief Scientific Officer | 1962 |
| Ms. Aimee Crombie Ph.D. | Senior VP and Head of Strategic Planning & Operations | — |
| Dr. Madhu Pudipeddi Ph.D. | Senior Vice President of Technical Operations | — |
| Mr. Robert A. Doody Jr. | Senior Vice President of Investor Relations | — |
| Ms. Michele Porreca M.B.A. | Chief People Officer | — |
| Dr. Andrew P. Combs Ph.D. | Executive VP & Chief Chemistry Officer | 1967 |
| Mr. Naveen Babbar Ph.D. | Senior Vice President of Translation Medicine | — |
| Dr. Wan-Jen Hong M.D. | Senior Vice President of Clinical Development | 1979 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 48.14
- MACD 12/26/9
- -0.07
- EMA 9 of MACD
- -0.10
- MACD histogram
- 0.03
- SMA 50
- $4.07
- Price below SMA 50
- EMA 50
- $4.05
- Price below EMA 50
- SMA 200
- $4.08
- Price below SMA 200
- EMA 200
- $3.74
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $12.00
- Average
- $12.00
- High
- $12.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -9.8 | -9.5 | ||||||||||
| 2022 | -24.9 | -13.7 | -18.5 | -36.7 | -13.6 | +24.0 | -5.7 | +42.6 | -13.8 | -1.8 | +0.3 | -8.6 |
| 2023 | +27.1 | -14.1 | -3.9 | -2.1 | -9.4 | -19.1 | -13.5 | +1.1 | -15.6 | -39.0 | +78.0 | +32.2 |
| 2024 | -19.4 | +31.5 | +3.3 | -19.6 | +3.2 | +3.3 | +69.0 | -8.0 | -59.4 | -40.9 | -15.3 | +21.9 |
| 2025 | -12.0 | -31.5 | +13.2 | +24.7 | -3.3 | -11.0 | -2.5 | +45.8 | +27.4 | +5.3 | -57.8 | +87.1 |
| 2026 | -32.2 | +36.0 | +26.2 | +51.6 | -16.6 | +39.5 | -6.3 | +27.6 | -28.8 | +2.4 | -1.6 |



